Obstetric outcome in pregnancy with thrombophilia: a comparative study of two different thromboprophylaxis regimes


  • Shilpa Asthana Department of Obstetrics and Gynecology, INHS Asvini, Mumbai, Maharashtra, India
  • Bandana Sodhi Department of Obstetrics and Gynecology, Moolchand Medcity, New Delhi, India
  • Satish Kumar Pathology and Transfusion Medicine, Armed Forces Transfusion Centre, Delhi Cant, New Delhi, India




Anti-phospholipid antibody syndrome, Ecosprin, LMWH, Obstetric outcome, Recurrent pregnancy loss, UFH, Thrombophilia, Thromboprophylaxis


Background: Thrombophilia in pregnancy is a leading cause of both maternal and fetal mortality and morbidity. Thromboprophylaxis is administered to the patients with thrombophilia with an aim to improve the obstetric outcome. Although various studies have proven the benefits of treating pregnant women with thrombophilia, few studies comparing the usage of Unfractionated Heparin (UFH) and Low Molecular Weight Heparin (LMWH) along with low - dose ecosprin in terms of obstetric outcome, incidence of IUGR, pre-eclampsia, mode of delivery, neonatal birth weight and adverse effects of therapy have been published. This study was undertaken to compare two different treatment modalities using either UFH or LMWH (along with low dose ecosprin) in pregnant patients with thrombophilia with respect to obstetric outcomes and incidence of adverse effects of therapy.

Methods: This randomised, prospective study was conducted in patients with a previous history of recurrent pregnancy losses or previous adverse pregnancy outcomes. Sixty patients diagnosed with thrombophilia were randomly divided into two groups of 30 patients each (Group I and II). Patients in Group I received Inj Unfractionated Heparin 5000 I.U. (s.c) twice daily and Tab Ecosprin 75 mg once daily and those in Group II received Inj LMWH (enoxaparin) 40 mg (s.c) once daily and Tab Ecosprin 75 mg once daily. These pregnancies were followed and the obstetrical outcome was determined. The data collected was analysed using the Student’s `t`test and Chi-square test. P values < 0.05 were considered statistically significant.

Results: There was no significant difference observed between two treatment groups with respect to pregnancy outcomes, incidence of IUGR, pre-eclampsia and mode of delivery (vaginal or by caesarean section). Treatment with a combination of LMWH and ecosprin administered to patients in Group II resulted in significantly higher neonatal birth weights.

Conclusions: Treatment with a combination of LMWH and ecosprin resulted in significantly higher neonatal birth weights as compared to a regime that comprised of UFH and ecosprin. There was no significant difference seen in patients who were treated with either UFH or LMWH along with low dose ecosprin in terms of obstetric outcome, incidence of IUGR, pre-eclampsia and mode of delivery. No thromboembolic events or side effects were witnessed in patients subjected to either of the two regimes using LMWH or UFH with low dose ecosprin, thus, highlighting the safety of the antithrombotic therapy during pregnancy as used in this study.


Simcox LE, Ormesher L, Tower C, Greer 1A. Thrombophilia and Pregnancy Complications. Int J Mol Sci. 2015;16(12):28418-28.

Battinelli EM, Marshall A, Connors JM. The role of thrombophilia in pregnancy. Thrombosis. 2013;2013.

James A; Committee on Practice Bulletins-Obstetrics. Practice bulletin no. 123: thromboembolism in pregnancy. Obstet Gynecol. 2011 Sep;118(3):718-29.

Bennett SA, Bagot CN, Arya R. Pregnancy loss and thrombophilia: the elusive link. Br J Haematol. 2012;157(5):529-42.

Sultan AA, West J, Tata LJ, Fleming KM, Nelson‐Piercy C, Grainge MJ. Risk of first venous thromboembolism in and around pregnancy: a population based cohort study. Br J Haematol. 2012;156(3):366-73.

Pabinger I. Thrombophilia and its impact on pregnancy. Thromb Res. 2009;123 Suppl 3:S16-S21.

Middeldorp S. Thrombophilia and pregnancy complications: cause or association? J Thromb Haemost. 2007;5 Suppl 1:276-282.

Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e691S-736S.

Pierangeli SS, Leader B, Barilaro G, Willis R, Branch DW. Acquired and inherited thrombophilia disorders in pregnancy. Obstet Gynecol Clin North Am. 2011;38(2):271-95.

Lockwood C. Thrombosis, thrombophilia, and thromboembolism: clinical updates in women are health care. ACOG. 2007;6(4).

Kher A, Bauersachs R, Nielsen JD. The management of thrombosis in pregnancy: role of LMWH. Thromb Haemost. 2007;97(4):505-13.

Xiao J, Xiong J, Zhu F, He L. Effect of prednisone, aspirin, low molecular weight heparin and intravenous immunoglobulin on outcome of pregnancy in women with antiphospholipid syndrome. Exp Therapeu Med. 2013;5(1):287-91.

Potdar N, Gelbaya TA, Konje JC, Nardo LG. Adjunct low-molecular-weight heparin to improve live birth rate after recurrent implantation failure: a systematic review and meta-analysis. Hum Reprod Update. 2013;19(6):674-84.

DeVries JIP, VanPampus MG, Hague WM, Bezemer PD, Joosten JH. On behalf of FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost. 2012;10:64-72.

American College of Obstetricians and Gynecologists: Practice Bulletin No. 132: antiphospholipid syndrome. Obstet Gynecol. 2012;120(6):1514-21.

Mantha S, Bauer KA, Zwicker JI. Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review. J Thromb Haemost. 2010;8(2):263-8.

Andersen AS, Berthelsen JG, Bergholt T. Venous thromboembolism in pregnancy: prophylaxis and treatment with low molecular weight heparin cta Obstet Gynecol. 2010;89:1515.

Tapson VF. Acute pulmonary embolism. N Engl J Med. 2008;358:1037.

Garcia DA, Spyropoulos AC. Update in the treatment of venous thromboembolism. Semin Respir Crit Care Med. 2008;29:40.

Leduc L, Dubois E, Takser L, Rey E, David M. Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. J Obstet Gynaecol Can. 2007;29(10):787-93.

McNamee K, Dawood F, Farquharson R. Recurrent miscarriage and thrombophilia: an update. Curr Opin Obstet Gynecol. 2012;24:229-34.

Regan L, Backos M, Rai. The investigation and treatment of couples with recurrent first trimester and second trimester miscarriages. RCOG Green-top Guideline No. 17. 2011;2011.

Cheung MW, Cheak AA, Ho RC. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatol 2010;49(2):281-8.

Giannakpoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368:1033.

Committee on Practice Bulletins—Obstetrics, American College of Obstetricians and Gynecologists. Practice Bulletin No. 132: Antiphospholipid syndrome. Obstet Gynecol. 2012;120(6):1514-21.

Erkan D, Kozora E, Lockshin MD. Cognitive dysfunction and white matter abnormalities in antiphospholipid syndrome. Pathophysiology. 2011;18(1):93.

Branch DW, Gibson M, Silver RM. Recurrent miscarriage. N Engl J Med. 2010;363:18.






Original Research Articles